EP 86: The Year 2022 in Review with Dr Sukh Nijjer

Parallax by Ankur Kalra

In this week’s Parallax Dr Kalra welcomes back Dr Nijjer for their annual review of the most impactful and controversial cardiovascular trials of 2022. Dr Sukh Nijjer is a Consultant Cardiologist in the UK, he is President of the Royal Society of Medicine and Honorary Senior Clinical Lecturer at Imperial College of London. The coronary physiology trial FLAVOUR was presented at ACC.22 by Dr Bon Kwon Koo. This South-Korean study compared the safety and efficacy of FFR and IVUS-guided stenting. Dr Nijjer interprets the findings and outlines the take-home messages by describing his practice. Following this, Dr Kalra and Dr Nijjer look at REVIVED-BCIS2 presented at ESC 2022 by Dr Divaka Perera. Dr Nijjer talks about the complexity of running this study that evaluated whether revascularization by PCI can improve outcomes in patients with ischemic left ventricular systolic dysfunction compared with optimal medical therapy. They distill some of the nuances for practice. Dr Nijjer summarises the all-comers PROTECTED TAVR trial that assessed the use of Sentinel® Cerebral Protection System in patients undergoing TAVR. We learn more about the secondary outcomes and the reception of the results. Dr Kalra shares how the new data impacted his approach. Last, they discuss the implications of Chinese CTS-AMI trial presented at AHA 22 by Dr Yuejin Yang. The trial showed that a traditional remedy, Tongxinluo improved the clinical outcomes of patients with STEMI. Dr Nijjer and Dr Kalra consider the meaning and impact of these trials such as CTS-AMI on Western medicine. How can we interpret some of the controversies from REVIVED? What can we learn from traditional medicinal remedies? What are the key takeaways for clinical practice from the reviewed trials? Questions and comments can be sent to “[e-mail]” and may be answered by Ankur in the next episode. Guest: @SukhNijjer, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.